A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 157 participants.
Also called NCT05615363
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 157 participants
- Registry
-
NCT05615363
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT05615363. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-10 (actual); primary completion 2024-10-21 (actual). Results posted on 2025-10-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
- Condition
- Cardiac Edema (CHF)
- Intervention (Drug)
- OPC 131461 10mg group
- Intervention (Drug)
- OPC 131461 5mg group
- Intervention (Drug)
- OPC 131461 2mg group
- Intervention (Drug)
- OPC 131461 1mg group
- Intervention (Drug)
- Placebo
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct05615363- Content hash
676cd81f0ee4b975a59f4dabc4f391b56fbe80fb43445552e4bdb3249c109abb